Polar Asset Management Partners Inc. Cuts Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Polar Asset Management Partners Inc. lessened its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 65.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 212,244 shares of the medical technology company's stock after selling 408,980 shares during the period. Polar Asset Management Partners Inc. owned 0.15% of Alphatec worth $1,948,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. R Squared Ltd acquired a new stake in shares of Alphatec during the 4th quarter worth about $29,000. Comerica Bank grew its position in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after acquiring an additional 1,248 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock valued at $43,000 after acquiring an additional 4,234 shares in the last quarter. Quarry LP grew its position in Alphatec by 79.2% in the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after acquiring an additional 2,375 shares in the last quarter. Finally, Newton One Investments LLC acquired a new position in Alphatec in the 4th quarter valued at about $50,000. Hedge funds and other institutional investors own 66.35% of the company's stock.

Insider Buying and Selling at Alphatec

In other news, EVP David Sponsel sold 33,732 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total transaction of $365,317.56. Following the completion of the sale, the executive vice president now owns 668,977 shares in the company, valued at $7,245,020.91. This represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Scott Lish sold 12,000 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $12.12, for a total value of $145,440.00. Following the sale, the chief operating officer now owns 826,251 shares of the company's stock, valued at $10,014,162.12. This trade represents a 1.43% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 113,798 shares of company stock worth $1,365,665. 20.90% of the stock is owned by insiders.

Alphatec Stock Down 0.3%

Shares of Alphatec stock traded down $0.04 on Friday, reaching $12.42. 1,784,042 shares of the company were exchanged, compared to its average volume of 2,047,763. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $13.14. The company has a market cap of $1.82 billion, a P/E ratio of -9.70 and a beta of 1.06. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The stock's 50 day moving average price is $11.29 and its 200-day moving average price is $10.64.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). The company had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business's quarterly revenue was up 22.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.34) earnings per share. As a group, equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ATEC. Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research report on Monday, April 14th. Wall Street Zen raised Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 target price (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.